Medicare, Eli Lilly

Medicare can now cover Eli Lilly’s Zepbound for sleep apnea, CMS says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.
Elli Lilly’s weight loss drug to be covered in Medicare insurance in US for THIS treatment - all you need to know
Eli Lilly’s obesity drug Zepbound is now covered by Medicare for sleep apnea treatment, expanding access to the costly medication. This comes after Zepbound’s FDA approval for a secondary use, allowing Medicare coverage.
Medicare Expands Coverage of Eli Lilly’s Weight-Loss Drug
Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f
Eli Lilly's Zepbound set to eclipse Wegovy in U.S. obesity drug market
Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge industry giants in upcoming market trends
Eli Lilly's obesity drug gets Medicare coverage for sleep apnea, CNBC reports
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on Wednesday, citing the Centers for Medicare & Medicaid Services.
Zepbound can now be covered by Medicare
El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly expand access to the popular, yet costly treatment.
FiercePharma6d
Lilly’s Zepbound expected to surpass Novo’s Wegovy to ‘dominate’ obesity market: GlobalData
Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...
Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver
The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli Lilly
Eli Lilly ( LLY 1.80%) and Novo Nordisk ( NVO 2.76%) are two of the most valuable healthcare stocks in the world, largely due ...
FiercePharma1d
Wegovy and Zepbound tipped to fuel $20B boom in heart failure market
GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...
Business Insider15h
CMS confirms to CNBC Medicare plans can now cover Zepbound for sleep apnea
The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using an Off-Brand Version
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version between February and March 2025.